Log In Sign up
The largest database of trusted experimental protocols

Rat igg2a 2a3

Manufactured by BioXCell
Visit Supplier
Sourced in United States

Rat IgG2a (2A3) is a laboratory reagent used in immunological research and applications. It is a monoclonal antibody that specifically recognizes the IgG2a subclass of immunoglobulins in rats. The product can be used for the detection, quantification, or purification of rat IgG2a in various experimental procedures.

Automatically generated - may contain errors

Lab products found in correlation

Mouse igg1 mopc 21, by BioXCell (2 mentions) Positive control rat anti mouse pd 1 rmp1 14, by BioXCell (2 mentions) Jes6 1, by BioXCell (2 mentions) Anti pd1 rmp1 14, by BioXCell (1 mentions) Rat igg1 hrpn, by BioXCell (1 mentions) Rat igg2b ltf 2, by BioXCell (1 mentions) Anti il 1β b122, by BioXCell (1 mentions) Rmp1 14, by BioXCell (1 mentions) Celline flask, by BD (1 mentions) Ghost dye, by Cytek Biosciences (1 mentions)

12 protocols using rat igg2a 2a3

1

Anti-PD-1 Antibody Inhibits Tumor Growth in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 6

The ability of anti-PD-1 antibodies to reduce tumor growth in mouse models was examined by injecting MC38 cells subcutaneously into the flanks of C57BL6/J mice. Mice were randomized into groups with an approximate 100 mm3 average tumor size on day 11 and injected intraperitoneally with 200 μg of anti-PD-1 antibody 13407. Repeat doses were administered on days 14, 18 and 21. Control antibodies, mouse IgG1 (MOPC-21), rat IgG2a (2A3), and positive control rat anti-mouse PD-1 (RMP1-14) were purchased from BioXcell. Tumor sizes were measured twice weekly and the experiment was terminated after 24 days. Tumor weights at the end of the experiment are shown in FIG. 5 and indicate that anti-PD-1 antibody 13407 reduced tumor growth in mice to a similar extent as the reference anti-PD-1 antibody.

US11384147B2. Anti-PD-1 antibodies and uses thereof (2022-07-12). Jounce Therapeutics, Inc. [US]. Inventors: George Robert Mabry, III [US], Stephen Sazinsky [US].
+ Open protocol
+ Expand
2

Murine Myocardial Infarction Model

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
In vivo repAMI was induced by transient occlusion of the left coronary artery (LCA) for 45 min followed by reperfusion for 1–5 days as described previously [30 (link),31 (link)]. C57BL/6J Pdcd1−/− and C57BL/6J wild-type mice were anesthetized by intraperitoneal injection of ketamine (bela-pharm, Vechta, Germany) and xylazine (Ceva Tiergesundheit, Düsseldorf, Germany). Mice were intubated and ventilated with 40% O2 and 1.6–2.0 Vol.% isoflurane (Piramal, Mumbai, India). Analgesia was maintained with buprenorphine. Left-lateral thoracotomy was performed followed by pericardiotomy and exposure of the LCA. The LCA was ligated for 45 min while maintaining anesthesia, followed by reperfusion. The tissue was then closed with sutures before the end of the anesthesia. For experiments involving antibodies, mice were injected intraperitoneally with 250 µg anti-PD1 (RMP1-14) or 250 µg rat IgG2a (2A3, both BioXCell, West Lebanon, NH, USA) every other day starting on day 8 before surgery, followed by day 2 after surgery. Analgesia was maintained with buprenorphine 3 times a day. Mice were killed with an isoflurane overdose.
Michel L., Korste S., Spomer A., Hendgen-Cotta U.B., Rassaf T, & Totzeck M. (2022). PD1 Deficiency Modifies Cardiac Immunity during Baseline Conditions and in Reperfused Acute Myocardial Infarction. International Journal of Molecular Sciences, 23(14), 7533.
+ Open protocol
+ Expand
3

Orthotopic and Heterotopic Cancer Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
For orthotopic lung cancer model, 10–12-week-old male C57Bl/6 mice were injected directly into the lungs with LLC-1 cells. For heterotopic subcutaneous colon cancer model, 0.5 × 106 CT-26 cells in 200 µL PBS were subcutaneously injected to the upper right flank of 10-week-old female Balb/c mice. Mice received an I.P. injection of anti-PD-1 (RMP1-14; 250 μg) or Rat IgG2a (2A3; 250 μg) (Bioxcell). Tumor size was assessed with Vernier calipers using the formula width2 × length × 0.5.
For more details, see Figs. 5a, 6a, and S5.
Voloshin T., Kaynan N., Davidi S., Porat Y., Shteingauz A., Schneiderman R.S., Zeevi E., Munster M., Blat R., Tempel Brami C., Cahal S., Itzhaki A., Giladi M., Kirson E.D., Weinberg U., Kinzel A, & Palti Y. (2020). Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunology, Immunotherapy, 69(7), 1191-1204.
+ Open protocol
+ Expand
4

Early-Life Anti-IL-2 Antibody Injection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were i.p. injected with a cocktail of two different anti-IL-2 monoclonal antibodies JES6-1 and S4B6-1 (BioXcell) or isotype matched control antibody (rat IgG2a, 2A3; BioXcell), 200 μg each, twice a week, starting from 5–7 days after birth.
Chinen T., Kannan A.K., Levine A.G., Fan X., Klein U., Zheng Y., Gasteiger G., Feng Y., Fontenot J.D, & Rudensky A.Y. (2016). An essential role for IL-2 receptor in regulatory T cell function. Nature immunology, 17(11), 1322-1333.
+ Open protocol
+ Expand
5

Monoclonal Antibodies for Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols
Purified monoclonal rat-anti-mouse 4–1BB (TKS-1) and its isotype control rat-IgG2a (2A3) used for injection were obtained from BioXCell. For flow cytometry, fluorescence conjugated antibodies specific for CD45, CD4, CD8, CD19, Foxp3, IFN-γ, IL-17, B220, CD11c, CD11b, Siglec-H, BST2 and CD16/32 antibodies were purchased from BioLegend.
Zhou J., You B, & Yu Q. (2019). Agonist-induced 4-1BB activation prevents the development of Sjӧgren’s syndrome-like sialadenitis in non-obese diabetic mice. Biochimica et biophysica acta. Molecular basis of disease, 1866(3), 165605.
+ Open protocol
+ Expand
6

Anti-PD-1 Antibody Inhibits Tumor Growth in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 6

The ability of anti-PD-1 antibodies to reduce tumor growth in mouse models was examined by injecting MC38 cells subcutaneously into the flanks of C57BL6/J mice. Mice were randomized into groups with an approximate 100 mm3 average tumor size on day 11 and injected intraperitoneally with 200 μg of anti-PD-1 antibody 13407. Repeat doses were administered on days 14, 18 and 21. Control antibodies, mouse IgG1 (MOPC-21), rat IgG2a (2A3), and positive control rat anti-mouse PD-1 (RMP1-14) were purchased from BioXcell. Tumor sizes were measured twice weekly and the experiment was terminated after 24 days. Tumor weights at the end of the experiment are shown in FIG. 5 and indicate that anti-PD-1 antibody 13407 reduced tumor growth in mice to a similar extent as the reference anti-PD-1 antibody.

US10654929B2. Antibodies to PD-1 and uses thereof (2020-05-19). Jounce Therapeutics, Inc. [US]. Inventors: George Robert Mabry, III [US], Stephen Sazinsky [US].
+ Open protocol
+ Expand
7

Inhibition of IFN-γ and IL-18 in Murine Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were injected with 500 μg of anti-IFN-γ (XMG1.2, BioXCell) or Rat IgG1 (HRPN, BioXCell) intraperitoneally at day 8, 10, 12, 14, 16 and 18 post infection. Mice were injected with 100 μg of anti-IL-18 (YIGIF74–1G7, BioxCell) or Rat IgG2a (2A3, BioxCell) intraperitoneally at day 9, 10, 11, 12 and 13 post infection.
Parsa R., London M., de Castro T.B., Reis B., des Amorie J.B., Smith J.G, & Mucida D. (2022). Newly recruited intraepithelial Ly6A+CCR9+CD4+ T cells protect against enteric viral infection. Immunity, 55(7), 1234-1249.e6.
+ Open protocol
+ Expand
8

T Cell Depletion for Tumor Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice received weekly i.p. injections (400μg in 100 μl PBS) of CD8+ T cell depleting antibody (53-6.72, BioXCell) or CD4+ T cell depleting antibody (GK1.5, BioXCell) beginning 4 days prior to tumor implantation. Control animals received either rat IgG2a (2A3, BioXCell) or rat IgG2b (LTF-2, BioXCell) isotype controls for CD8+ and CD4+ T cell depletion studies respectively. Depletion was confirmed using flow cytometry.
Bucsek M.J., Qiao G., MacDonald C.R., Giridharan T., Evans L., Niedzwecki B., Liu H., Kokolus K.M., Eng J.W., Messmer M.N., Attwood K., Abrams S.I., Hylander B.L, & Repasky E.A. (2017). β-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy. Cancer research, 77(20), 5639-5651.
+ Open protocol
+ Expand
9

PD-1 and IL-1β Blockade in Il17a-GFP Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
For PD-1 blockade, Il17a-GFP mice were injected intraperitoneally with 200 μg of anti-PD-1 (RMP1-14, BioXcell) or isotype control Rat IgG2a (2A3, BioXcell) antibodies for three consecutive days. Mice were analyzed 24 h after the third antibody injection. For IL-1β blockade, Il17a-GFP mice were injected intraperitoneally with 200 μg of anti-IL-1β (B122, BioXcell) or isotype control polyclonal Armenian hamster IgG (BioXcell) twice a week for 2 weeks. Mice were analyzed 24 h after the last antibody injection.
Lau Y.J., Hu B.S., Wu W.L., Lin Y.H., Chang H.Y, & Shi Z.Y. (2000). Identification of a Major Cluster of Klebsiella pneumoniae Isolates from Patients with Liver Abscess in Taiwan. Journal of Clinical Microbiology, 38(1), 412-414.
+ Open protocol
+ Expand
10

Anti-CSF1R and Anti-CD40 Therapy for KPC Mice

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
KPC mice with 3–6 mm tumors were injected with purified anti-CSF1R (anti-CD115, clone AFS98)(18 (link)) derived from a hybridoma generously provided by Dr. Miriam Merad (Icahn School of Medicine at Mount Sinai, New York, NY). Mice received 1 mg/mouse IP on day −3 and day 0 (e.g., day of T-cell therapy), followed by bi-weekly injections of 0.5 mg/mouse IP for 8 or 28 days. A separate cohort of KPC mice was treated once with 100 μg agonistic anti-CD40 (FGK145 hybridoma kindly provided by Dr. Stephen Schoenberger, La Jolla Institute for Allergy and Immunology, San Diego, CA) or isotype control (Rat IgG2a, 2A3; Bioxcell). Anti-CSF-1R and anti-CD40 were purified from culture supernatants of hybridomas grown in a CELLine Flask (BD) in serum-free Hybridoma medium (Sigma) or purchased from BioXcell.
Stromnes I.M., Burrack A.L., Hulbert A., Bonson P., Black C., Brockenbrough J.S., Raynor J.F., Spartz E.J., Pierce R.H., Greenberg P.D, & Hingorani S.R. (2019). Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma. Cancer immunology research, 7(6), 977-989.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!